The role of Interim-PET in DLBCL is controversial. To determine predictive value of Interim-PET on PFS we enrolled 88 first-line DLBCL patients treated with 6-8 R-CHOP regardless of Interim-PET results. PET/CT were performed at diagnosis, after 2-4 courses and at the end of therapy with central reviewing according to visual dichotomous criteria. 
INTRODUCTION
Despite attempts to increase the efficacy of conventional chemotherapy, no more than 60% of patients diagnosed with Diffuse Large B-Cells Lymphoma (DLBCL) are potentially cured with a prolonged PFS, when treated with Rituximab-CHOP-like regimens. The current salvage therapy seems to be inadequate in non-responding patients: only 30-35% of resistant or relapsed patients can achieve a prolonged PFS with high dose chemotherapy followed by autologous stem cell transplantation in the Rituximab era. 1 For personal use only. on . by guest www.bloodjournal.org From Indeed, a good strategy might be a first line risk-tailored therapy in the poor prognosis patients.
The prognosis of DLBCL is mostly established on the basis of the clinical characteristics defined by the International Prognostic Index (IPI) and more recently by the gene expression profiling subtypes. 2, 3 IPI is a recognized predictor of treatment outcome, but there is a considerable variation between the outcome of individual patients within the same IPI prognostic group. Response to treatment may be another important predictor of outcome with the advantage of addressing the management for the individual patient. The monitoring of treatment efficacy is generally performed with evaluation of tumor size using conventional anatomical imaging modalities, commonly computed tomography (CT).
Unfortunately, CT has the disadvantage of not distinguishing between a real tumor mass and residual tissue mass, and also, assessment of early response is not reliable during treatment with CT since tumor volume reduction may require time.
In the diagnosis of DLBCL, 18-Fluorodeoxyglucose positron emission tomography (18- FDG-PET/CT) has proved to be highly sensitive in determining sites of disease. [4] [5] [6] In addition, residual FDG positivity at the end of therapy is predictive for survival. [5] [6] [7] [8] Initial reports suggested that PET/CT scans, performed early during treatment (Interim-PET) after 2-4 courses of CHOP chemotherapy, could identify patients likely to relapse. 9 , 10 Itti et al reported the value of I-PET in predicting the outcome of DLBCL patients with different hystological subtypes who had been treated with different chemotherapy regimens (R-CHOP, ACVBP) using a Delta-SUV based criteria; 10, 11 however, a significant portion of patients had a prolonged survival in a remission condition despite positive interim PET scan. Indeed, the significance of interim-PET in aggressive NHL is still unconfirmed and its use is not approved outside of clinical trials. 6, 11, 12 In our multicenter retrospective study we analyzed a homogeneous cohort of newly diagnosed DLBCL patients treated with R-CHOP who underwent PET scan at diagnosis, 
PATIENTS AND METHODS

Patients population and Treatment
Eighty-eight newly diagnosed DLBCL patients were included in this study. Follow up data were recorded at scheduled visits. No patient was lost to follow up.
All patients were treated according to departmental protocol. Depending on the stage and site of presentations, patients were given either R-CHOP alone or a combination of R-CHOP and radiotherapy. All patients were treated with standard R-CHOP21 13 
PET scans
All studies were 18F-FDG-PET/CT scans, acquired from the orbits to the proximal third of the thighs.
Scans were acquired respectively on the following tomographs: Philips Gemini, General Electrics Discovery ST, General Electrics Discovery LS, Siemens Biograph 16 HI-REZ. All patients fasted at least 6 hours before intravenous injection of 37 MBq/10kg of 18F-glucose. All patients had glucose levels between 90 and 160 mg/dl at the moment of injection; all scans were done within a range of 60-90 minutes after injection. The PET scans were performed at 60 minutes in 82/88 patients; the remaining 6 patients had PET scans acquired later than usual (at 90 minutes) because of practical issues, such a delays in arrival of patients or materials, unexpected hyperglicemia, incorrect transmission of clinical data, ect, leading to last-minute rescheduling of the daily workplan. However, if this happened at staging, the following studies were scheduled to respect the initial time point, so the near totality of patients had scans acquired at the same timing.
PET scans were performed in all patients at diagnosis, during treatment (I-PET) after two, three or four cycles of chemotherapy and at the end of therapy (F-PET) approximately one month after the end of chemoimmunotherapy ± radiotherapy. Fifty-eight patients had I-PET performed after 2 courses and 30 patients had I-PET performed after 3 (9 patients) or 4 (21 patients) courses of chemotherapy.
All interim results were interpreted as positive or negative by visual dichotomous response criteria according to the 5 Point Score system defined at the First Consensus Conference in Deauville 2009. 15 For personal use only. on October 31, 2017. by guest www.bloodjournal.org From 6 5-PS were defined as follow: 1 -No uptake; 2 -Uptake equal or less than mediastinum; 3 -Uptake more than mediastinum but less than liver; 4 -Uptake moderately increased compared to the liver at any site; 5 -Uptake markedly increased compared to the liver at any site or/and new sites of disease.
We set the cut-off value at grade 4 of the 5 -PS. When appreciation of difference on a visual basis was difficult, a SUVmax-based analysis (liver vs lesion) was performed.
The results of all scans were centrally reviewed at the Turin University Centre.
A deltaSUV analysis between baseline and Interim PET (Basal-Interim deltaSUVmax) or between baseline and Final PET (Basal-Final deltaSUVmax) was also performed on a subgroup of 46 patients available and quantifiable directly at the Turin Centre. The methodology was the same as that used by Lin et al: 16 using a steep colour scale and normalizing at the liver, deltaSUVmax between basal and interim scan was referred to the hottest lesion at each study, with a cut-off value at 66%.
All final scans were evaluated using Juweid criteria which uses mediastinal blood pool as reference background for the visual evaluation of residual activity in masses equal to or greater than 2 cm. 
RESULTS
Clinical Characteristics
The study included 88 patients. Clinical features were: median age 55 years (range 18- A Total of 264 PET scans was performed and centrally reviewed and concordance in the reading among centers was 96%. Sixty-three patients (72%) were negative and 25 (28%) positive at I-PET; 77 patients (88%) were negative and 11 (12%) positive at F-PET. Fifteen out of twenty-five (60%) I-PET positive patients converted to negative at F-PET, while only 1/63 (2%) I-PET negative case had a positive F-PET (Table 2) . At the end of therapy, 79 patients (90%) achieved a complete response (CR) and nine (10%) were non responders.
The concordance between clinical CR and F-PET negativity was 97%: two patients, whilst in CR, had false positive final scans due to parotid and colorectal cancer (histologically confirmed) respectively. At the time of this analysis, 11 patients relapsed or progressed despite I-PET negativity and 9 patients with I-PET positive failed; PPV (positive predictive value) and NPV (negative predictive value) of the I-PET by Progression were 36.0% and 82,5% respectively, with a sensitivity of 45% and a specificity of 76,5%.
We also analyzed the possible correlation between I-PET performed after 2 or 3-4 courses of chemotherapy and F-PET. Fifty-eight patients had I-PET performed after 2 courses: all 39 patients negative at the I-PET remained negative at the F-PET and 12 of 19 patients positive at the I-PET converted to negative at F-PET. Thirty patients had I-PET performed 
Treatment Outcome
With a median follow-up of 26.2 months, 2-year Overall Survival (OS) and 2-year Progression Free Survival (PFS) were 91% and 77% respectively for the whole series of patients ( fig 1A and 1B) . There was a weak correlation between PFS and I-PET results, with a minor difference in 2y-PFS rates between I-PET negative and positive patients: 85% for negative and 72% for positive patients (p .047) (Figure 2A) . Conversely, F-PET strongly predicted 2y-PFS (p <.001): 83% for negative and 64% for positive patients respectively ( Figure 2B ). In univariate analyses with PFS as outcome measure, elevated LDH value, ≥ score, I-PET and F-PET positivity were predictors of lower PFS rates. The use of G-CSF or number of R-CHOP courses before I-PET did not influence PFS rates (table 3 and table   4 ). Two independent bivariate analyses by Cox models were performed to properly evaluate the prognostic role of I-PET and F-PET results for PFS. In model one, only F-PET retained its prognostic value compared to I-PET with an adjusted HR of 5 
DISCUSSION
Aim of our study was to determine the predictive value of I-PET and F-PET on the outcome in a series of DLBCL patients homogeneously treated with R-CHOP chemotherapy. In our population 40% of patients had a poor risk IPI score, according to reported DLBCL different prognostic subgroup's rates. 2 Our results confirmed, as in others series, the strong predictive value of the F-PET on PFS. On the contrary, I-PET failed to clearly identify patients with different PFS rates. Although, in our series of patients a negative interim 18F-FDG-PET/CT scan predicted a good outcome with a 2 yrs-PFS of 85%, a positive interim PET scan was not able to identify patients with a worse prognosis:
notably, in our study positive I-PET patients had a only slightly inferior 2-yrs PFS (72%).
Indeed, negative predictive value for I-PET was 82,5%, but positive predictive value of I-PET was only 36,0%. To better analyze the predictive value of I-PET and F-PET, we performed two independent bivariate analyses by Cox models. The results of both models underlined that only F-PET and IPI score remained independent prognostic factors for PFS (Table 3 and 4) , whereas I-PET had a very weak correlation with the outcome.
Only a portion of patients with DLBCL are cured by standard chemotherapy with Rituximab. 13, 14 Salvage high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT) may rescue some patients with refractory or relapsed disease.
However, the chance to salvage refractory/relapsed patients prior treated with R-CHOP is nowadays largely unsatisfactory with less than 30-35% of these patients being cured even after HDC+ASCT. 1, 17 The upfront use of this intensive approach in poor prognosis patients is controversial with different results among published reports [18] [19] [20] and it is not recommended outside of clinical trials, because a proportion of patients may experience a long PFS with R-CHOP.
Therefore the possibility to find a tool that is able to predict an unfavorable outcome early for end-of therapy evaluation in lymphoma, and are designed to achieve the best possible safety in defining a patient as negative at the end of therapy; on the other hand, the Deauville system for interim evaluation is flexible and gives the possibility to change the cut-off value depending on different factors (hystology, number of chemotherapy courses, end point of different protocols).
As DLBCL patients respond to therapy in a continuous modality, with a relatively higher rate of minimal residual uptake compared to HL patients at interim evaluation, we chose to set the cut-off value at grade 4 of the 5-PS: in fact, by considering the liver as reference background, the system tends to be more "forgiving", in order to have less false positives.
In our study we willingly chose to use two different methods of evaluation, considering that Meignan et al 27 suggested that a quantitative approach based on SUV (max) reduction between baseline PET and interim PET may have a higher predictive value than visual analysis when PET was performed at two cycles, but was equivalent to visual analysis at four cycles. Therefore it appears that interpretation criteria of interim PET are far from being properly defined for the evaluation of tumor response and chemosensitivity.
Moreover, in a more recently study published by Casasnovas et al 28 There are some potential explanations for false positive scans. FDG as a marker has not a so high specificity because it is taken up also in infections and inflammatory processes. In conclusion, our data would indicate that, in DLBCL patients undergoing to R-CHOP as first-line treatment, positive I-PET scans did not identify high risk patients with a worse outcome while only negative I-PET results seems to predict a favourable outcome.
Moreover, the F-PET scans confirmed its high predictive value for PFS. Larger prospective trials and optimization and standardization of criteria for Interim PET evaluation for DLBCL patients are needed to assess the real prognostic value of Interim PET results. 
